Avacincaptad Pegol Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Nov 8, 2023.

Usual Adult Dose for Macular Degeneration

2 mg (0.1 mL of 20 mg/mL solution) by intravitreal injection to each affected eye once monthly. Can be given approximately every 28 days plus or minus 7 days.

Duration of therapy: Up to 12 months.

Comments:

• Before the intravitreal injection, check the intraocular pressure (IOP).
• If necessary, ocular hypotensive medicine can be administered to reduce IOP.

Use: For the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS:

• Ocular or periocular infections
• Active intraocular inflammation

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug should be administered by a qualified physician.
• Adequate anesthesia and topical microbicide should be given prior to intravitreal injection.
• Prior to use, allow the solution to reach room temperature.
• Each vial should only be used to treat a single eye.
• Do not use the filter needle for the intravitreal injection.
• Immediately inject the dose after its preparation.
• The manufacturer product information should be consulted.

Storage requirements:

• Store in the refrigerator at temperatures between 2C to 8C (36F to 46F).
• This drug may be kept at room temperature for up to 24 hours. Protect from light.
• Do not freeze. Do not shake.

Reconstitution/preparation techniques:

• Prepare the intravitreal injection aseptically.
• The manufacturer product information should be consulted.

Monitoring:
Ocular: Elevated intraocular pressure, neovascular AMD, optic nerve head perfusion

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Instruct patients to report any symptoms suggestive of endophthalmitis (e.g., eye pain, redness of the eye, photophobia, blurring of vision) immediately.
• This drug may develop neovascular AMD, endophthalmitis, elevated intraocular pressure and retinal detachments.
• Patients may experience temporary visual disturbances and blurring after an intravitreal injection.
• Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Frequently asked questions

• How do Izervay and Syfovre compare?

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer